Drugs that contain Risdiplam

1. Drug name - EVRYSDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(10 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

CN104349777B GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

CN104349777A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

CN106459092A GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

CN106459092B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN334397B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN201647038542A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP2812004B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A2 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A4 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3406252A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3406252B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3143025A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP3143025B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.75MG/ML FOR SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.